Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
S&P 500, Dow score best day in 2 weeks, Nasdaq erases weekly loss as Netflix, Alphabet jump
09:48pm, Friday, 20'th Jan 2023 MarketWatch
U.S. stocks end sharply higher Friday, but the S&P 500 and Dow still booked weekly losses.
US Markets End the Week With Gains as Tech Stocks Soar
06:10pm, Friday, 20'th Jan 2023
The Nasdaq was up by roughly 2.7% during the session on Friday, Jan. 20, while the Dow and S&P 500 also posted gains to close out the trading week.
FDA rejects Eli Lilly's accelerated approval application for Alzheimer's drug
05:56pm, Friday, 20'th Jan 2023
Yahoo Finance Live anchors Dave Briggs and Seana Smith discuss the move lower in Eli Lilly stock.
FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug
05:52pm, Friday, 20'th Jan 2023 Zacks Investment Research
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Google Layoffs 12K Employees, Netflix's Q4 Earnings And CEO Steps Down, FDA Rejects Eli Lilly's Alzheimer's Candidate: Top Stories Friday, Jan. 20
03:21pm, Friday, 20'th Jan 2023 Benzinga
Here's a round-up of stories from around the globe and from various media outlets.
Benzinga
Google To Fire 12K Employees Worldwide; Extends Support Packages
Alphabet Inc.'s (NASDAQ: GOOG) (NASDAQ: G
Pharma Stock Roundup: LLY's Donanemab Gets FDA's CRL, MRNA RSV Jab Study Succeeds
02:23pm, Friday, 20'th Jan 2023 Zacks Investment Research
FDA gives CRL to Lilly's (LLY) Alzheimer's candidate, donanemab. Moderna's (MRNA) phase III study on its mRNA-based RSV vaccine candidate in older adults meets primary efficacy endpoints
FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug
02:18pm, Friday, 20'th Jan 2023
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Eli Lilly shares slide as US regulator wants more data on its potential Alzheimer's treatment
01:56pm, Friday, 20'th Jan 2023
Eli Lilly and Co (NYSE:LLY) shares sank after it emerged that the US Food and Drug Administration (FDA) said needed to see more data on the company's application to accelerate approval of its potenti
Tech Stocks Get Netflix Boost Amid Jittery Wider Market On Friday, Dow Stares At 4th Straight Loss
11:30am, Friday, 20'th Jan 2023 Benzinga
U.S. stocks look set for a positive start on Friday, reversing course from the sell-off seen in the past three sessions.
What Happened: Traders may have to contend with Fed speeches and housing mark
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug
09:58am, Friday, 20'th Jan 2023
Eli Lilly stock dipped Friday after the FDA unexpectedly rejected its request for an accelerated approval of its Alzheimer's treatment. The post In A Stunner, Eli Lilly Stock Falls After FDA Delivers
Why the FDA didn't grant an approval to Lilly's Alzheimer's drug
09:23am, Friday, 20'th Jan 2023
Eli Lilly & Co. LLY, -0.26% now plans to seek full approval of its experimental Alzheimer's disease treatment after the Food and Drug Administration refused to grant a speedier approval using less rig
FDA rejects Eli Lilly's proposed Alzheimer's treatment, says more data needed
12:16am, Friday, 20'th Jan 2023 MarketWatch
The setback could delay a potential commercial introduction of the highly anticipated drug by at least several months, if the Food and Drug Administration eventually decides to approve it.
FDA rejects Eli Lilly's proposed Alzheimer's treatment, says more data needed
07:16pm, Thursday, 19'th Jan 2023
U.S. drug regulators rejected Eli Lilly & Co.'s proposed new Alzheimer's disease treatment, saying they need more data from clinical testing, according to the company.
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
05:19pm, Thursday, 19'th Jan 2023 Benzinga
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.
In large-cap land, there two two o
Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement
10:00am, Thursday, 19'th Jan 2023
INDIANAPOLIS , Jan. 19, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2022 financial results on Thursday, Feb. 2, 2023. Lilly will also conduct a conference c
